Drug Trial Radar · NCT01178073
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Last checked: Nov 20, 2026Latest source record: Sep 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
610
Actual
Start
Oct 1, 2010
Primary completion
Jul 31, 2014
Study completion Jul 31, 2014
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Gilead Sciences
- First posted
- Aug 9, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial Hypertension. This will be assessed by time to the first clinical failure event.
Conditions
- Hypertension, Pulmonary
Interventions
ambrisentanDrug
ambrisentan (target dose: 10mg)
tadalafilDrug
tadalafil (target dose: 40mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With First Adjudicated Clinical Failure (CF) Event, Death, Hospitalisation for Worsening PAH, Disease Progression, Unsatisfactory Long-term Clinical Response, All Through FAVTime frame: From Baseline up to the Final Assessment Visit (FAV) (average of 609 days)
Locations
143 sites in 14 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Mobile, Alabama
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
La Jolla, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
Torrance, California
GSK Investigational Site
Aurora, Colorado
GSK Investigational Site
Gainesville, Florida
GSK Investigational Site
Jacksonville, Florida
GSK Investigational Site
Kissimmee, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Weston, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Decatur, Georgia
GSK Investigational Site
Oakbrook Terrace, Illinois
GSK Investigational Site
Carmel, Indiana
GSK Investigational Site
Iowa City, Iowa
GSK Investigational Site
Kansas City, Kansas
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
Portland, Maine
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Springfield, Massachusetts
GSK Investigational Site
Ann Arbor, Michigan
GSK Investigational Site
Detroit, Michigan
GSK Investigational Site
Troy, Michigan
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Morristown, New Jersey
GSK Investigational Site
Newark, New Jersey
GSK Investigational Site
New Hyde Park, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
Rochester, New York
Showing 40 of 143 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.